ABP-1011T / AB Pharma - LARVOL DELTA

A phase IIa clinical trial of ABP1011T monotherapy in patients with advanced malignant solid tumors. (ASCO 2025) - P1/2 | "Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. The results of ABP1011T in Phase IIa exploratory study showed that ABP1011T was well tolerated, and its mono-therapy showed varying degrees of tumor shrinkage in advanced sarcoma , SCLC, EC, BC, and cervical cancer that had been treated with Anlotinib and PD-1, etc. A phase IIb study of ABP1011T will be conducted to further validate the safety, tolerability and efficacy in advanced malignant solid tumors."

Clinical • Metastases • Monotherapy • P2a data • Bladder Cancer • Cervical Cancer • Colorectal Cancer • Endocrine Cancer • Esophageal Cancer • Genito-urinary Cancer • Hypertension • Lung Cancer • Neuroendocrine Tumor • Oncology • Osteosarcoma • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • EGFR • FGFR1 • FLT1 • KIT • MET • PD-1